DUBLIN--(BUSINESS WIRE)--The "US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.
The US generic drug market has witnessed a transformation over the last three decades. From less than 20% of the total prescriptions, generic drugs now account for the majority of the total prescriptions dispensed in the United States. During 2011-2018, the US generic drug market grew at a CAGR of 12% and currently represents a multibillion dollar industry.
The biggest catalyst of this industry is the significantly lower price of generics compared to branded drugs. Although generics are chemically identical to their branded counterparts, they are typically sold at substantial discounts from the branded price. This has enabled governments and third-party payers to save billions of dollars in healthcare expenditures and resulted in lower co-payments for patients.
Other factors such as patent expiration of blockbuster innovator drugs, ageing population and an increasing prevalence of chronic diseases have also acted as catalysts for this market.
Study Coverage
The report provides a comprehensive insight into the historical and current trends as well as the future prospects of the generic drug market in the United States.
This study serves as an exceptional tool to understand the sales trends, volume trends, growth, key segments, competitive structure, regulations, major manufacturer, major distributors, top drugs, manufacturing requirements, opportunities and future prospects of the US generic drug market.
This report can serve as an excellent guide for manufacturers, consultants, researchers, marketing strategists and all those who plan to foray into the US generic drug market in any form.
Topics Covered
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2
Stakeholders
2.3 Data Sources
2.4 Market Estimation
2.5
Forecasting Methodology
3 Executive Summary
4 US Generic Drug Market - Introduction
4.1 What are Generic Drugs?
4.2
Unbranded and Branded Generics
4.3 Authorized Generics
4.4
Commoditized and Specialty Generics
5 Why is the US Generic Drug Market So Lucrative
5.1 Patent Expiry
of Blockbuster Drugs
5.2 Significant Price Differential between
Generics and Innovator Drugs
5.3 Savings for the Government and
Third-Party Payers
5.4 Incentives for Dispensing and Prescribing
Generic Drugs
5.5 Reimbursement and Lower Co-payments
5.6
Biosimilars
6 Global Generic Drug Market
6.1 Market Performance
6.1.1
Volume Trends
6.1.2 Value Trends
6.2 Market Breakup by Country
6.3
Market Forecast
6.4 Most Prescribed Generic and Branded Drugs
7 US Generic Drug Market
7.1 US Pharmaceutical Market Performance
7.2
US Generic Drug Market Performance
8 Market Breakup by Segment
8.1 Unbranded Generics
8.2 Branded
Generics
9 Market Breakup by Therapy Area
9.1 CNS
9.2 Cardiovascular
9.3
Dermatology
9.4 Genitourinary/Hormonal
9.5 Respiratory
9.6
Rheumatology
9.7 Diabetes
9.8 Oncology
9.9 Others
10 Market Breakup by Drug Delivery
10.1 Oral
10.2 Injectables
10.3
Dermal/Topical
10.4 Inhalers
11 Market Breakup by Distribution Channel
11.1 Retail Pharmacies
11.2
Hospital Pharmacies
12 US Generic Drug Market - SWOT Analysis
12.1 Overview
12.2
Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 US Generic Drug Market - Value Chain Analysis
13.1 Research and
Development
13.2 Raw Material Procurement
13.3 Manufacturing
13.4
Marketing
13.5 Distribution
14 Pricing Mechanism and Profit Margins at Various Levels of the Supply Chain
15 Porter's Five Forces Analysis
15.1 Overview
15.2 Bargaining
Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree
of Rivalry
15.5 Threat of New Entrants
15.6 Threat of
Substitutes
16 US Generic Drug Market - Competitive Landscape
16.1 Competitive
Structure
16.2 Breakup of Key Players
16.4 Most Prescribed
Generic Drugs
16.5 Market Breakup by Distribution
16.6 Pricing
Dynamics
17 Regulations in the US Generic Drug Industry
17.1 Overview of
Pharmaceutical Regulations
17.2 Drug Applications
17.3 Patents
and Market Exclusivity
17.4 Regulatory Requirements for Generic
Drugs
17.5 The Hatch-Waxman Act
17.6 Certifications
17.7
Other Important Considerations
18 US Generic Drug Market: Key Success Factors
19 US Generic Drug Market: Road Blocks
20 Requirements for Setting Up a Generic Drug Manufacturing Plant
20.1
Manufacturing Process
20.2 Raw Material Requirements
20.3 Raw
Materials Pictures
20.4 Land and Construction Requirements
20.5
Machinery and Infrastructure Requirements
20.6 Machinery Pictures
20.7
Plant Layout
20.8 Packaging Requirements
20.9 Utility
Requirements
20.10 Manpower Requirements
21 US Generic Drug Market - Key Company Profiles
21.1 Teva
21.2
Mylan
21.3 Actavis
21.4 Sandoz
21.5 Sun Pharma
21.6
Par Pharmaceuticals
21.7 Endo Pharmaceuticals
21.8 Lupin
Pharmaceuticals
21.9 Dr. Reddy's
21.10 Hospira
For more information about this report visit https://www.researchandmarkets.com/research/sw2j6k/united_states?w=4
